Find out what is happening at your local American Heart
Science News (Scientific Sessions)
Science News from Scientific Sessions 2015
This is your home for comprehensive Science News coverage of the most interesting, important, and ground-breaking studies and scientific developments from AHA's Scientific Sessions 2015 in Orlando, Florida.
One Year Follow-up Results From AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation With Algisyl-LVR in the Treatment of Heart Failure
The-First-in-Man Randomized Trial of a β3-adrenoceptor Agonist in Chronic Heart Failure - The BEAT-HF Trial
Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Primary Results of a Randomized, 2 x 2 Factorial, Placebo-Controlled, Double-Blind Clinical Trial
ANNEXA™-R Part 2: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Sustained Reversal of Rivaroxaban-Induced Anticoagulation in Older Subjects by Andexanet Alfa (PRT064445), a Universal Antidote for Factor XA (FXA) Inhibitors
Prevention of Acute Kidney Injury by Nitric Oxide During and After Prolonged Cardiopulmonary Bypass. A Double Blind Randomized Controlled Trial
A Randomized, Placebo Controlled Trial of Late Na Channel Inhibition (ranolazine) in Coronary Microvascular Dysfunction (CMD): Impact on Angina and Myocardial Ischemia
ALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 With Potential for Effective Quarterly or Possibly Bi-Annual Dosing: Results of Single-Blind, Placebo-Controlled, Phase 1 Single-Ascending Dose (SAD), and Multi-Dose (MD) Trial in Adults With Elevated LDL-C, on and off Statins
In case you missed our previous daily science:
Saturday, November 7
Preview: Coronary Artery Disease and Interventions Science Mark Creager, MD, president of the American Heart Association, and Elliott Antman, MD immediate past president, preview some of the late breaking clinical science that will be presented on coronary artery disease and interventions.
Preview: Registry Science Mark Creager, MD, president of the American Heart Association, and Robert Bonow, MD past president, preview select registry science that will be presented at Scientific Sessions 2015 in Orlando.
Scientific Sessions 2015 Welcome and Program Highlights American Heart Association President Mark Creager, MD welcomes attendees to Scientific Sessions 2015 in Orlando, and Program Chair Frank Sellke, MD and Vice Chair Eric Peterson, MD provide an overview of select late breaking clinical science.
A Randomized Trial of Liraglutide for High-Risk Heart Failure Patients with Reduced Ejection Fraction
Nitrate's Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction (NEAT-HFpEF)
Oral sGC Stimulator Vericiguat in Patients with Worsening Chronic Heart Failure and Reduced Ejection Fraction - The SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with REDUCED EF (SOCRATES-REDUCED) Study
Remote Patient Management After Discharge of Hospitalized Heart Failure Patients: The Better Effectiveness After Transition - Heart Failure Study
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure(COSMIC-HF): Final Results from a Double-blind, Randomized, Placebo-controlled, Multicenter Study
Monday, November 9
Cutting Edge Technologies in EP Gordon Tomaselli and panelists Janathan Picinni, MD, and Fred Masoudi, MD discuss the science presented in CS.02 Cutting Edge Technologies in EP.
Next Generation Registries Panelists Marc Ruel, MD, MPH, Bob Harrington, MD, and Jane Newburger, MD, MPH discuss the science presented in clinical science special report 01 Novel Findings from Next Generation Registries.
Decreasing the Global Burden of Disease Donna Arnett, PhD interviews panelists Sidney Smith, MD Thomas Granziano, MD and Allison Goldfine, MD about LBCT.02 Decreasing the Global Burden of Disease: Breakthroughs in Prevention.
Results of the ROC Trial Bob Neumar, MD, immediate past chair of the Emergency Cardiovascular Care Committee, interviews investigator Graham Nichol, MD, about Results of the Resuscitation Outcomes Consortium Trial.
Decreasing the Global Burden of Cardiovascular Disease: Moving the Needle
The Efficacy and Safety of Varenicline, a Selective Alpha4beta2 Nicotinic Receptor Partial Agonist, for Smoking Cessation in Patients Hospitalized with Acute Coronary Syndrome: A Randomized Controlled Trial
Impact of a Comprehensive Lifestyle Peer-group-based Intervention on Cardiovascular Risk Factors: A Randomized Controlled Trial
Clinical Trial of a Mobile Health Intervention for Simultaneous versus Sequential Diet and Activity Change
The Effect of Disclosing Genomic Risk of Coronary Heart Disease on Low-density Lipoprotein Cholesterol Levels: The Myocardial Infarction Genes (MI-GENES) Study
Empagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus at High Cardiovascular Risk
Implementation of a Multidimensional Bundle for Dispatcher Telephone CPR in a Horizontal Dispatch System is Associated with Increased Bystander CPR and Good Neurological Survival From Out-of-hospital Cardiac Arrest
Telecommunicator CPR Intervention Improves Recognition of Cardiac Arrest and Time to First Chest Compression
Large Randomized Trial of Continuous versus Interrupted Chest Compressions in Out-of-hospital Cardiac Arrest: Results of the Resuscitation Outcomes Consortium CCC Trial
Tuesday, November 10
Managing Risk Factors for CAD Donna Arnett, PhD and panelists Christie Ballantyne, MD, Marc Ruel, MD discuss the science presented in CS.03 Managing Risk Factors for Coronary Artery Disease: Clinical Trial Updates.
ACS and PCI The Continuum of Care Alice Jacobs, MD, Kristin Newby, MD, MHS, and James De Lemos, MD discuss the science presented in LBCT.03 Acute Coronary Syndromes and Percutaneous Intervention: The Continuum of Care.
Cholesterol Treatment Targets and Clinical Outcomes: A JUPITER Trial Update
Relationship Between High-Density Lipoprotein Cholesterol and Cardiovascular and Non-Cardiovascular Mortality: A Population-Based Study of More than 630,000 Individuals Without Prior Cardiovascular Conditions in Ontario, Canada
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes Follow-On Blood Pressure Study
Revascularization in Patients With Diabetes and Multivessel Coronary Artery Disease: A Population Based Evaluation of Outcomes
Characteristics and Impact of Bystander Cardiopulmonary Resuscitation Following Pediatric Out of Hospital Cardiac Arrest in the United States: A Study From the Cardiac Arrest Registry to Enhance Survival (CARES)